
## Angeles Rovirosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6143588/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiotherapy and Oncology, 2009, 91, 150-156.	0.3	217
2	Entzündungshemmende Effekte von niedrigdosierter Strahlentherapie. Strahlentherapie Und Onkologie, 2012, 188, 975-981.	1.0	119
3	GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update – Improvement by cross sectional imaging based treatment planning and stepping source technology. Radiotherapy and Oncology, 2017, 122, 248-254.	0.3	111
4	Endobronchial metastatic disease: Analysis of 32 cases. , 1996, 62, 249-252.		103
5	A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psycho-Oncology, 2007, 16, 971-979.	1.0	103
6	Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the GRUP ONCOLOGIC CATALÀ-OCCITÀ. International Journal of Radiation Oncology Biology Physics, 1999, 44, 47-52.	0.4	73
7	Individualized 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow. Journal of Contemporary Brachytherapy, 2017, 3, 270-276.	0.4	44
8	ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). Journal of Contemporary Brachytherapy, 2018, 10, 260-266.	0.4	44
9	Uterine sarcomas in breast cancer patients treated with tamoxifen. International Journal of Gynecological Cancer, 2006, 16, 861-865.	1.2	43
10	ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy). Journal of Contemporary Brachytherapy, 2016, 4, 336-343.	0.4	43
11	Granulocyte macrophage–colony–stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 747-754.	0.4	41
12	Hypofractionated high-dose-rate plesiotherapy in nonmelanoma skin cancer treatment. Brachytherapy, 2015, 14, 859-865.	0.2	41
13	Prospective Evaluation of Squamous Cell Carcinoma <i></i> and Carcinoembryonic Antigen as Prognostic Factors in Patients with Cervical Cancer. Tumor Biology, 2003, 24, 156-164.	0.8	36
14	Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? a retrospective study of prognostic factors of 60 patients stratified by stages. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1320-1329.	0.4	35
15	Salivary scintigraphy for assessing the protective effect of pilocarpine in head and neck irradiated tumours. Nuclear Medicine Communications, 2001, 22, 651-656.	0.5	30
16	Acoustic analysis after radiotherapy in T1 vocal cord carcinoma: a new approach to the analysis of voice quality. International Journal of Radiation Oncology Biology Physics, 2000, 47, 73-79.	0.4	29
17	Laparoscopic Lymphadenectomy in Advanced Cervical Cancer: Prognostic and Therapeutic Value. International Journal of Gynecological Cancer, 2013, 23, 1675-1683.	1.2	28
18	Analysing the integration of MR images acquired in a non-radiotherapy treatment position into the radiotherapy workflow using deformable and rigid registration. Radiotherapy and Oncology, 2016, 119, 179-184.	0.3	26

#	Article	IF	CITATIONS
19	CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Research, 2005, 25, 1765-71.	0.5	26
20	Quality assurance of interstitial brachytherapy technique in lip cancer: comparison of actual performance with the Paris System recommendations. Radiotherapy and Oncology, 1996, 38, 145-151.	0.3	24
21	Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. Modern Pathology, 2020, 33, 128-137.	2.9	23
22	Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules. Radiotherapy and Oncology, 2015, 116, 143-148.	0.3	20
23	Vaginal cuff brachytherapy in endometrial cancer – a technically easy treatment?. Cancer Management and Research, 2017, Volume 9, 351-362.	0.9	20
24	Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal. Radiation Oncology, 2014, 9, 260.	1.2	19
25	Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck. Clinical and Translational Oncology, 2007, 9, 244-250.	1.2	18
26	Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonephric adenocarcinoma of the uterine corpus. Gynecologic Oncology, 2003, 90, 458-461.	0.6	17
27	Three or Four Fractions of 4–5 Gy per Week in Postoperative High-Dose-Rate Brachytherapy for Endometrial Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, 418-423.	0.4	17
28	Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients. Clinical and Translational Oncology, 2016, 18, 925-930.	1.2	17
29	Multidisciplinary consensus on the criteria for fertility preservation in cancer patients. Clinical and Translational Oncology, 2022, 24, 227-243.	1.2	17
30	Consensus on treatment of endometrium carcinoma with brachytherapy. Clinical and Translational Oncology, 2012, 14, 263-270.	1.2	15
31	Recommendations of the Spanish brachytherapy group (GEB) of Spanish Society of Radiation Oncology (SEOR) and the Spanish Society of Medical Physics (SEFM) for high-dose rate (HDR) non melanoma skin cancer brachytherapy. Clinical and Translational Oncology, 2018, 20, 431-442.	1.2	15
32	M-CAVI, A Neoadjuvant Carboplatin-based Regimen for the Treatment of T2-4N0M0 Carcinoma of the Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 344-348.	0.6	14
33	Cavitary Pulmonary Metastases in Transitional Cell Carcinoma of the Urinary Bladder. Urologia Internationalis, 1992, 48, 102-104.	0.6	13
34	Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clinical and Translational Oncology, 2008, 10, 303-306.	1.2	13
35	Daily schedule for high-dose-rate brachytherapy in postoperative treatment of endometrial carcinoma. Clinical and Translational Oncology, 2013, 15, 111-116.	1.2	13
36	Undifferentiated uterine sarcoma: a rare, not well known and aggressive disease: report of 13 cases. Archives of Gynecology and Obstetrics, 2014, 290, 993-997.	0.8	13

#	Article	lF	CITATIONS
37	Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy. Strahlentherapie Und Onkologie, 2016, 192, 248-253.	1.0	13
38	Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma. Brachytherapy, 2017, 16, 1169-1174.	0.2	13
39	The role of brachytherapy (interventional radiotherapy) for primary and/or recurrent vulvar cancer: a Gemelli Vul.Can multidisciplinary team systematic review. Clinical and Translational Oncology, 2021, 23, 1611-1619.	1.2	13
40	Decentralisation of radiation therapy. Is it possible and beneficial to patients? Experience of the first 5 years of a satellite radiotherapy unit in the province of Tarragona, Spain. Reports of Practical Oncology and Radiotherapy, 2015, 20, 141-144.	0.3	12
41	Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity. Clinical and Translational Oncology, 2013, 15, 602-607.	1.2	11
42	Late C2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction (α/β=3Gy) at 2 cm 3 of vagina. Journal of Contemporary Brachytherapy, 2018, 10, 40-46.	0.4	11
43	Is anti-inflammatory radiotherapy an effective treatment in trochanteritis?. British Journal of Radiology, 2017, 90, 20160520.	1.0	10
44	A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results. Brachytherapy, 2017, 16, 147-152.	0.2	10
45	Are endometrial cancer radiotherapy results age related?. Clinical and Translational Oncology, 2018, 20, 1416-1421.	1.2	10
46	Pathologic prognostic factors in stage l–III uterine carcinosarcoma treated with postoperative radiotherapy. Archives of Gynecology and Obstetrics, 2014, 290, 329-34.	0.8	9
47	Rectal contrast increases rectal dose during vaginal cuff brachytherapy. Brachytherapy, 2016, 15, 35-39.	0.2	9
48	The usefulness of fleet rectal enemas on high-dose-rate intracavitary cervical cancer brachytherapy. A prospective trial. Journal of Contemporary Brachytherapy, 2017, 3, 224-229.	0.4	9
49	Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy. Cancer Research and Treatment, 2015, 47, 473-479.	1.3	9
50	Acoustic voice analysis in different phonetic contexts after larynx radiotherapy for T1 vocal cord carcinoma. Clinical and Translational Oncology, 2008, 10, 168-174.	1.2	8
51	Whole abdominal radiotherapy in ovarian cancer. Reports of Practical Oncology and Radiotherapy, 2010, 15, 27-30.	0.3	8
52	Postoperative endometrial carcinoma treated with external beam irradiation plus vaginal-cuff brachytherapy. Is there a dose relationship with G2 vaginal complications?. Reports of Practical Oncology and Radiotherapy, 2020, 25, 227-232.	0.3	8
53	Oncological Results of Laparoscopically Assisted Radical Vaginal Hysterectomy in Early-Stage Cervical Cancer: Should We Really Abandon Minimally Invasive Surgery?. Cancers, 2021, 13, 846.	1.7	8
54	Endoluminal High-Dose-Rate Brachytherapy with a Palliative aim in Esophageal Cancer: Preliminary Results at the Institut Gustave Roussy. Tumori, 1995, 81, 359-363.	0.6	7

#	Article	IF	CITATIONS
55	Correlation between clinical findings and magnetic resonance imaging for the assessment of local response after standard treatment in cervical cancer. Reports of Practical Oncology and Radiotherapy, 2013, 18, 214-219.	0.3	7
56	The effect of lymphadenectomy and radiotherapy on recurrence and survival in endometrial carcinoma. Experience in a population reference centre. Reports of Practical Oncology and Radiotherapy, 2015, 20, 50-56.	0.3	7
57	Ultrasound-guided transvaginal thrombin injection of uterine arteries pseudoaneurysms. British Journal of Radiology, 2017, 90, 20160913.	1.0	7
58	Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group. Clinical and Translational Oncology, 2022, 24, 254-265.	1.2	7
59	How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?. Clinical and Translational Oncology, 2009, 11, 681-687.	1.2	6
60	Endometrial stromal sarcoma. Is there a place for radiotherapy?. Clinical and Translational Oncology, 2010, 12, 226-230.	1.2	6
61	Is one brachytherapy fraction of 7ÂGy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?. Clinical and Translational Oncology, 2020, 22, 1295-1302.	1.2	6
62	EQD2 Analyses of Vaginal Complications in Exclusive Brachytherapy for Postoperative Endometrial Carcinoma. Cancers, 2020, 12, 3059.	1.7	6
63	Meningeal fibrosarcoma: a case report and review of the literature. Acta Neurologica Belgica, 1992, 92, 30-5.	0.5	6
64	Radiation Pneumonitis. Clinical Pulmonary Medicine, 2010, 17, 218-222.	0.3	5
65	In Regard to Chapman etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1317-1318.	0.4	5
66	Does postoperative irradiation improve survival in early-stage endometrial cancer?. Brachytherapy, 2018, 17, 912-921.	0.2	5
67	Radiotherapy is safe in patients with implantable cardiac devices. Analysis of a systematic interrogation follow-up. Clinical and Translational Oncology, 2020, 22, 2286-2292.	1.2	5
68	A CT-based simulation for head and neck tumors in centers without CT-simulator and 3D-planning system. Medical Dosimetry, 1995, 20, 111-115.	0.4	4
69	In relation to the arytenoid edema in the radiotherapy of the early vocal cord cancer: Arytenoid shielding and small size of the field. Radiotherapy and Oncology, 1997, 45, 209-210.	0.3	4
70	Simulation by a diagnostic CT for the early vocal cord carcinoma. Medical Dosimetry, 1997, 22, 13-16.	0.4	4
71	CONSIDERING QUALITY OF VOICE IN EARLY VOCAL CORD CARCINOMA. Radiotherapy and Oncology, 2000, 56, 271-272.	0.3	4
72	Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus. Clinical and Translational Oncology, 2015, 17, 581-589.	1.2	4

#	Article	IF	CITATIONS
73	Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy. Reports of Practical Oncology and Radiotherapy, 2016, 21, 213-218.	0.3	4
74	Oncology: Management of Elderly Cancer Patients. BioMed Research International, 2018, 2018, 1-2.	0.9	4
75	Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis. Brachytherapy, 2020, 19, 60-65.	0.2	4
76	EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates. Radiologia Medica, 2022, 127, 341-348.	4.7	4
77	Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists. Cancers, 2022, 14, 906.	1.7	4
78	578Considerations after simulation by a diagnostic CT of 25 tino vocal cord carcinomas. Quality assurance. Radiotherapy and Oncology, 1996, 40, S148.	0.3	3
79	Global radiation oncology waybill. Reports of Practical Oncology and Radiotherapy, 2013, 18, 321-328.	0.3	3
80	Results of Vaginal Relapse and Toxicity of 3 192 ir HDR Brachytherapy Schedules in Postoperative Endometrial Carcinoma International Journal of Radiation Oncology Biology Physics, 2017, 99, E309.	0.4	3
81	Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis. Clinical and Translational Oncology, 2022, 24, 875-881.	1.2	3
82	Endobronchial metastases in colorectal adenocarcinoma. Tumori, 1992, 78, 270-3.	0.6	3
83	Radiotherapy in the Maxillary Hemangioma. Tumori, 1996, 82, 610-613.	0.6	2
84	Overall Interval Brachytherapy Treatment Time In High Dose Rate Brachytherapy (HDRBT) For Endometrial Carcinoma (EC). International Journal of Radiation Oncology Biology Physics, 2011, 81, S477.	0.4	2
85	New developments and controversies in cervical cancer. Reports of Practical Oncology and Radiotherapy, 2018, 23, 481-483.	0.3	2
86	An MRI comparative image evaluation under diagnostic and radiotherapy planning set-ups using a carbon fibre tabletop for pelvic radiotherapy. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 296-303.	0.6	2
87	MRI prostate contouring is not impaired by the use of a radiotherapy image acquisition set-up. An intra- and inter-observer paired comparative analysis with diagnostic set-up images. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 107-113.	0.6	2
88	In response to Korreman s. et al. Radiation oncologists are, above all, medical doctors. Clinical and Translational Radiation Oncology, 2021, 28, 116-117.	0.9	2
89	Endobronchial metastatic disease: Analysis of 32 cases. Journal of Surgical Oncology, 1996, 62, 249-252.	0.8	2
90	Recurrence and survival in surgically treated endometrioid endometrial cancer. Clinical and Translational Oncology, 2008, 10, 505-511.	1.2	1

#	Article	IF	CITATIONS
91	PO-240 DAILY HDR BRACHYTHERAPY IN THE POSTOPERATIVE SETTING OF ENDOMETRIAL CARCINOMA. Radiotherapy and Oncology, 2012, 103, S97.	0.3	1
92	Comparative Results of Vaginal Relapses and Toxicity of 2 Protracted 192-Ir HDR Brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). International Journal of Radiation Oncology Biology Physics, 2014, 90, S493.	0.4	1
93	Comparison of Three Short Fractionation Schedules for Exclusive High-Dose Rate Brachytherapy in Intermediate-Risk Endometrial Carcinoma. Brachytherapy, 2016, 15, S127.	0.2	1
94	EP-1967: Preliminary results of a new brachytherapy schedule in postoperative endometrial carcinoma. Radiotherapy and Oncology, 2016, 119, S932.	0.3	1
95	Economic Impact of Decreasing the Number of Fractions in Postoperative Brachytherapy of Endometrial Carcinoma by One Third International Journal of Radiation Oncology Biology Physics, 2018, 102, e400.	0.4	1
96	PO-0813: Charlson Index in Very Elderly Patients Receiving Radiotherapy for Endometrial Cancer Treatment. Radiotherapy and Oncology, 2018, 127, S424.	0.3	1
97	G2 Late Vaginal Toxicity Associated with 68Gy EQD2 at 2cm3 of Vaginal in External Beam Irradiation Plus Vaginal-Cuff Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E356.	0.4	1
98	Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study Journal of Clinical Oncology, 2012, 30, 270-270.	0.8	1
99	Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy. Tumori, 1995, 81, 359-63.	0.6	1
100	In Vivo Verification of Treatment Source Dwell Times in Brachytherapy of Postoperative Endometrial Carcinoma: A Feasibility Study. Journal of Personalized Medicine, 2022, 12, 911.	1.1	1
101	Real-size CT Slices to Optimize Brachytherapy in the Plastic Tube Technique for Oral Cavity Neoplasms. Medical Dosimetry, 1998, 23, 109-111.	0.4	0
102	Neoadjuvant chemotherapy (NC) in patients with locally advanced cervical cancer (LACC). European Journal of Cancer, 1999, 35, S239.	1.3	0
103	Acute Toxicity Report for Combined Sorafenib and Radiation Treatment in Phase 1 Multicentric Trial for Conservative Management of Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S83-S84.	0.4	0
104	Workshop in gynaecology: Cervical cancer. Reports of Practical Oncology and Radiotherapy, 2013, 18, S38-S39.	0.3	0
105	Body Mass Index and Doses at Organs at Risk Evaluated by CT in a Mediterranean Postoperative Vaginal Cuff Brachytherapy (VCB) Cancer Population. International Journal of Radiation Oncology Biology Physics, 2014, 90, S494.	0.4	0
106	The Spanish Group of Brachytherapy: A Successful Story. Brachytherapy, 2016, 15, S95-S96.	0.2	0
107	Comparison of 3 Short Brachytherapy Schedules After Postoperative External Beam Radiation Therapy in Endometrial Carcinoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, E317-E318.	0.4	0
108	EP-1320: Postoperative radiotherapy results of serous endometrial carcinoma: 34 cases during 2003-2014. Radiotherapy and Oncology, 2016, 119, S619.	0.3	0

#	Article	IF	CITATIONS
109	EP-1727: MRI quality analysis between radiotherapy and diagnostic setup using a carbon fibre tabletop. Radiotherapy and Oncology, 2017, 123, S948-S949.	0.3	0
110	EP-1504: Postoperative radiotherapy for endometrial carcinoma in elderly patients. Radiotherapy and Oncology, 2018, 127, S815-S816.	0.3	0
111	Response to Escande et al.: Magnetic guided brachytherapy: Time for non-pelvic cancer? Example from tongue brachytherapy. Radiotherapy and Oncology, 2021, 155, e3-e4.	0.3	0
112	Consensus and recommendations on vaginal-cuff Brachytherapy of the Spanish Brachytherapy Groups of SEOR and SEFM. Clinical and Translational Oncology, 2021, 23, 1193-1200.	1.2	0
113	Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain). Journal of Clinical Oncology, 2009, 27, e16550-e16550.	0.8	0
114	Analgesic effects of low-dose radiotherapy in greater trochanteric pain syndrome: results in a clinical series of 155 patients with recurrent or refractory symptoms. Clinical and Translational Oncology, 2021, , 1.	1.2	0